Claims for Patent: 10,201,541

Summary for Patent: 10,201,541

Title:	Compositions and methods for treating HCV
Abstract:	This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
Inventor(s):	Collins; Christine A. (Skokie, IL), Cohen; Daniel E. (Highland Park, IL), Koev; Gennadiy (Libertyville, IL), Krishnan; Preethi (Gurnee, IL), Pilot-Matias; Tami J. (Green Oaks, IL)
Assignee:	ABBVIE INC. (North Chicago, IL)
Application Number:	15/398,390
Patent Claims:	1. A pharmaceutical composition comprising an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is compound A or a salt thereof: ##STR00005## wherein therapeutic agent B is compound B or a salt thereof: ##STR00006## wherein the molar ratio of therapeutic agent A to therapeutic agent B is about 1:20 to about 1:2000. 2. The pharmaceutical composition of claim 1, wherein the amount of therapeutic agent B is about 200 mg. 3. The pharmaceutical composition of claim 1, wherein the amount of therapeutic agent A is from about 5 mg to about 200 mg. 4. The pharmaceutical composition of claim 1, wherein the composition further comprises one or more additional therapeutic agents. 5. The pharmaceutical composition of claim 4, wherein the one or more additional therapeutic agents include an HCV protease inhibitor. 6. The pharmaceutical composition of claim 5, wherein the one or more additional therapeutic agents include a cytochrome P-450 inhibitor. 7. The pharmaceutical composition of claim 1, further comprising an HCV protease inhibitor and a cytochrome P-450 inhibitor. 8. The pharmaceutical composition of claim 7, wherein the cytochrome P-450 inhibitor is ritonavir. 9. The pharmaceutical composition of claim 1, wherein therapeutic agent B is a sodium salt of compound B.